Cargando…

Perforating Colitis Secondary to Immune Checkpoint Inhibitor Use in a Patient With Pericolonic Involvement by Rosai-Dorfman Disease

Recently, the use of immunotherapy has increased substantially for the treatment of several malignancies. It is associated with several gastrointestinal adverse events; however, severe complications such as intestinal perforation are rare. We present a 75-year-old man with metastatic melanoma, prese...

Descripción completa

Detalles Bibliográficos
Autores principales: Bakhshwin, Ahmed, Robertson, Jessica, Sarwate, Mrinal, Roberts, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762925/
https://www.ncbi.nlm.nih.gov/pubmed/36561494
http://dx.doi.org/10.14309/crj.0000000000000900
_version_ 1784852953123782656
author Bakhshwin, Ahmed
Robertson, Jessica
Sarwate, Mrinal
Roberts, Daniel
author_facet Bakhshwin, Ahmed
Robertson, Jessica
Sarwate, Mrinal
Roberts, Daniel
author_sort Bakhshwin, Ahmed
collection PubMed
description Recently, the use of immunotherapy has increased substantially for the treatment of several malignancies. It is associated with several gastrointestinal adverse events; however, severe complications such as intestinal perforation are rare. We present a 75-year-old man with metastatic melanoma, presented with profuse diarrhea and abdominal pain, after ipilimumab and nivolumab administration. Shortly after, he developed fulminant colitis and intestinal perforation and was found to have concurrent Rosai-Dorfman disease of pericolonic lymph nodes. With the increasing use of immunotherapy, reporting of serious adverse events and their mimics is essential. In addition, further studies are required to investigate whether an association exists between Rosai-Dorfman disease and immunotherapy.
format Online
Article
Text
id pubmed-9762925
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer
record_format MEDLINE/PubMed
spelling pubmed-97629252022-12-21 Perforating Colitis Secondary to Immune Checkpoint Inhibitor Use in a Patient With Pericolonic Involvement by Rosai-Dorfman Disease Bakhshwin, Ahmed Robertson, Jessica Sarwate, Mrinal Roberts, Daniel ACG Case Rep J Case Report Recently, the use of immunotherapy has increased substantially for the treatment of several malignancies. It is associated with several gastrointestinal adverse events; however, severe complications such as intestinal perforation are rare. We present a 75-year-old man with metastatic melanoma, presented with profuse diarrhea and abdominal pain, after ipilimumab and nivolumab administration. Shortly after, he developed fulminant colitis and intestinal perforation and was found to have concurrent Rosai-Dorfman disease of pericolonic lymph nodes. With the increasing use of immunotherapy, reporting of serious adverse events and their mimics is essential. In addition, further studies are required to investigate whether an association exists between Rosai-Dorfman disease and immunotherapy. Wolters Kluwer 2022-12-19 /pmc/articles/PMC9762925/ /pubmed/36561494 http://dx.doi.org/10.14309/crj.0000000000000900 Text en © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Case Report
Bakhshwin, Ahmed
Robertson, Jessica
Sarwate, Mrinal
Roberts, Daniel
Perforating Colitis Secondary to Immune Checkpoint Inhibitor Use in a Patient With Pericolonic Involvement by Rosai-Dorfman Disease
title Perforating Colitis Secondary to Immune Checkpoint Inhibitor Use in a Patient With Pericolonic Involvement by Rosai-Dorfman Disease
title_full Perforating Colitis Secondary to Immune Checkpoint Inhibitor Use in a Patient With Pericolonic Involvement by Rosai-Dorfman Disease
title_fullStr Perforating Colitis Secondary to Immune Checkpoint Inhibitor Use in a Patient With Pericolonic Involvement by Rosai-Dorfman Disease
title_full_unstemmed Perforating Colitis Secondary to Immune Checkpoint Inhibitor Use in a Patient With Pericolonic Involvement by Rosai-Dorfman Disease
title_short Perforating Colitis Secondary to Immune Checkpoint Inhibitor Use in a Patient With Pericolonic Involvement by Rosai-Dorfman Disease
title_sort perforating colitis secondary to immune checkpoint inhibitor use in a patient with pericolonic involvement by rosai-dorfman disease
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762925/
https://www.ncbi.nlm.nih.gov/pubmed/36561494
http://dx.doi.org/10.14309/crj.0000000000000900
work_keys_str_mv AT bakhshwinahmed perforatingcolitissecondarytoimmunecheckpointinhibitoruseinapatientwithpericolonicinvolvementbyrosaidorfmandisease
AT robertsonjessica perforatingcolitissecondarytoimmunecheckpointinhibitoruseinapatientwithpericolonicinvolvementbyrosaidorfmandisease
AT sarwatemrinal perforatingcolitissecondarytoimmunecheckpointinhibitoruseinapatientwithpericolonicinvolvementbyrosaidorfmandisease
AT robertsdaniel perforatingcolitissecondarytoimmunecheckpointinhibitoruseinapatientwithpericolonicinvolvementbyrosaidorfmandisease